Literature DB >> 15738663

Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds.

W D Yang1, R R Gomes, M Alicknavitch, M C Farach-Carson, D D Carson.   

Abstract

Perlecan, a heparan sulfate proteoglycan, is widely distributed in developing and adult tissues and plays multiple, important physiological roles. Studies with knockout mouse models indicate that expression of perlecan and heparan sulfate is critical for proper skeletal morphogenesis. Heparan sulfate chains bind and potentiate the activities of various growth factors such as fibroblast growth factor 2 (FGF-2). Previous studies indicate that important biological activities are associated with the heparan sulfate-bearing domain I of perlecan (PlnDI; French et al. J. Bone Miner. Res. 17 , 48, 2002). In the present study, we have used recombinant, glycosaminoglycan-bearing PlnDI to reconstitute three-dimensional scaffolds of collagen I. Collagen I fibrils bound PlnDI much better than native collagen I monomers or heat-denatured collagen I preparations. Heparitinase digestion demonstrated that recombinant PlnDI was substituted with heparan sulfate and that these heparan sulfate chains were critically important not only for efficient integration of PlnDI into scaffolds, but also for FGF-2 binding and retention. PlnDI-containing collagen I scaffolds to which FGF-2 was bound sustained growth of both MG63, an osteoblastic cell line, and human bone marrow stromal cells (hBMSCs) significantly better than scaffolds lacking either PlnDI or FGF-2. Collectively, these studies demonstrate the utility of PlnDI in creating scaffolds that better mimic natural extracellular matrices and better support key biological activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15738663      PMCID: PMC1635240          DOI: 10.1089/ten.2005.11.76

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  57 in total

1.  Development of tailor-made collagen-glycosaminoglycan matrices: EDC/NHS crosslinking, and ultrastructural aspects.

Authors:  J S Pieper; T Hafmans; J H Veerkamp; T H van Kuppevelt
Journal:  Biomaterials       Date:  2000-03       Impact factor: 12.479

2.  Uterine stromal cell chondroitin sulfate proteoglycans bind to collagen type I and inhibit embryo outgrowth in vitro.

Authors:  D D Carson; J Julian; A L Jacobs
Journal:  Dev Biol       Date:  1992-02       Impact factor: 3.582

3.  Defining the domains of type I collagen involved in heparin- binding and endothelial tube formation.

Authors:  S M Sweeney; C A Guy; G B Fields; J D San Antonio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

4.  Three-dimensional composite of demineralized bone powder and collagen for in vitro analysis of chondroinduction of human dermal fibroblasts.

Authors:  S Mizuno; J Glowacki
Journal:  Biomaterials       Date:  1996-09       Impact factor: 12.479

5.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins.

Authors:  S Knox; J Melrose; J Whitelock
Journal:  Proteomics       Date:  2001-12       Impact factor: 3.984

6.  Matrix glycosaminoglycans in the growth phase of fibroblasts: more of the story in wound healing.

Authors:  M A Kosir; C C Quinn; W Wang; G Tromp
Journal:  J Surg Res       Date:  2000-07       Impact factor: 2.192

Review 7.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 8.  Heparin and heparan sulfate: structure and function.

Authors:  Dallas L Rabenstein
Journal:  Nat Prod Rep       Date:  2002-06       Impact factor: 13.423

9.  The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.

Authors:  J M Whitelock; A D Murdoch; R V Iozzo; P A Underwood
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

10.  Physiological strains induce differentiation in human osteoblasts cultured on orthopaedic biomaterial.

Authors:  F Di Palma; M Douet; C Boachon; A Guignandon; S Peyroche; B Forest; C Alexandre; A Chamson; A Rattner
Journal:  Biomaterials       Date:  2003-08       Impact factor: 12.479

View more
  28 in total

Review 1.  Strategies for controlled delivery of growth factors and cells for bone regeneration.

Authors:  Tiffany N Vo; F Kurtis Kasper; Antonios G Mikos
Journal:  Adv Drug Deliv Rev       Date:  2012-02-04       Impact factor: 15.470

2.  Repair of cartilage defects in arthritic tissue with differentiated human embryonic stem cells.

Authors:  Tsaiwei Olee; Shawn P Grogan; Martin K Lotz; Clifford W Colwell; Darryl D D'Lima; Evan Y Snyder
Journal:  Tissue Eng Part A       Date:  2013-10-19       Impact factor: 3.845

3.  Growth factor delivery through self-assembling peptide scaffolds.

Authors:  Rachel E Miller; Paul W Kopesky; Alan J Grodzinsky
Journal:  Clin Orthop Relat Res       Date:  2011-10       Impact factor: 4.176

4.  Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels.

Authors:  Kelsea M Hubka; Daniel D Carson; Daniel A Harrington; Mary C Farach-Carson
Journal:  Acta Biomater       Date:  2019-07-24       Impact factor: 8.947

5.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

6.  COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.

Authors:  Juan Arredondo; Marian Lara; Fiona Ng; Danielle A Gochez; Diana C Lee; Stephanie P Logia; Joanna Nguyen; Ricardo A Maselli
Journal:  Hum Genet       Date:  2013-11-27       Impact factor: 4.132

7.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

8.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

9.  Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells.

Authors:  Arivalagan Muthusamy; Carlton R Cooper; Ronald R Gomes
Journal:  BMC Biochem       Date:  2010-11-03       Impact factor: 4.059

Review 10.  Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.

Authors:  Kathryn D Rodgers; James D San Antonio; Olena Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.